Becton, Dickinson and Company (NYSE:BDX) Given Average Recommendation of “Hold” by Brokerages

Shares of Becton, Dickinson and Company (NYSE:BDX) have been assigned an average recommendation of “Hold” from the eleven research firms that are presently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $211.4444.

Several equities research analysts have recently issued reports on BDX shares. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price objective for the company. in a report on Friday, May 2nd. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. William Blair downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Finally, Raymond James Financial downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock worth $579,206 over the last ninety days. 0.36% of the stock is currently owned by insiders.

Institutional Trading of Becton, Dickinson and Company

A number of large investors have recently bought and sold shares of BDX. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company in the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. REAP Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 55 shares during the period. Finally, Cornerstone Planning Group LLC grew its position in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $199.2480 on Thursday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a fifty day moving average price of $179.66 and a 200 day moving average price of $196.25. The company has a market cap of $57.11 billion, a P/E ratio of 35.84, a PEG ratio of 1.48 and a beta of 0.20. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the prior year, the company earned $3.50 earnings per share. The business’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.